Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

Nanoliposomal irinotecan (nal‐IRI) is a liposomal formulation of irinotecan with a longer half‐life (t(1/2)), higher plasma total irinotecan (tIRI), and lower SN‐38 maximum concentration (C (max)) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal‐IRI was performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Adiwijaya, BS, Kim, J, Lang, I, Csõszi, T, Cubillo, A, Chen, J‐S, Wong, M, Park, JO, Kim, JS, Rau, KM, Melichar, B, Gallego, JB, Fitzgerald, J, Belanger, B, Molnar, I, Ma, WW
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697569/
https://www.ncbi.nlm.nih.gov/pubmed/28445610
http://dx.doi.org/10.1002/cpt.720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697569/
https://www.ncbi.nlm.nih.gov/pubmed/28445610
http://dx.doi.org/10.1002/cpt.720

Ejemplares similares